This page shows the latest Ranbaxy news and features for those working in and with pharma, biotech and healthcare.
Drilling down into the data provides a mixed picture for the pharma industry - at one end of the scale is Ranbaxy, which has published no results for any of the 35
The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around 52m, and those judgments have also been upheld by the General Court of the EU.
The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
The Swiss firm has managed to delay some generic forms of its drug onto the market until last year, when Ranbaxy was granted approval to sell its copycat form of valsartan.
Actos has generated more than $16bn in sales since its 1999 release, according to court filings, but now also faces generic competition from India's Ranbaxy Laboratories.
Ranbaxy Laboratories. ... Mylan and Ranbaxy, which are also defendants in the case, are not part of the settlement.
More from news
Approximately 6 fully matching, plus 92 partially matching documents found.
The acquisition of this portfolio with sales of INR 150 Crores, will help Dr Reddy's maintain a competitive edge with fellow Indian rival Sun Pharmaceuticals, following its acquisition of Ranbaxy
But for the likes of GSK, Novartis and Lilly with their asset swap agreement, Forest Laboratories and its acquisition of Actavis, and the various dealings at Merck &Co, BMS, Ranbaxy and
The total cost of the all-stock acquisition is $4.0bn (an 18% premium), $3.2bn in stock and nearly $800m of Ranbaxy debt. ... Eclipsing all else will be restoring FDA confidence. To this end immediate remedial action will involve management restructuring
Ranbaxy Laboratories/ Sun Pharmaceuticals. Acquisition. Generics including Lipitor, Nexium, Diovan. 3, 200.
Since 2008, more foreign companies such as Takeda, Daiichi Ranbaxy and others have been allowed to set operations in the country, increasing competition and consolidation.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil,
At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...